ProB) Plus 1

ProB) Plus 1

$36.10
RV58A

This unique probiotic contains as well as 20 billion shelf-stable probiotic bacteria, Germinated barley malt powder which reduces colonic mucosal inflammation, and thus may help prevent colon cancer as well as APS, Astragalus Polysaccharide which promotes probitotic growth.

 

Ingredients

Serving Size: 1 Scoop (4.36g)

Servings Per Container: 30
Astragalus Poysaccharide (APS)
Germinated Barley Malt Powder (1660mg)
Probiotic Blend (20 billion live organisms)
Lactobacillus plantarum
Lactobacillus rhamnosus
Bifidobacterium infantis
Bifidobacterium bifidum
Lactobacillus paracasei
Lactobacillus salivarius
Non-GMO Maltodextrin
 

ProB)Plus 1

129 gram powder

Actions

Maintains and stabilizes gut microflora

Increases microflora after antibiotic therapy

Modulates systemic immunity and intestinal microbiota

Reduces colonic mucosal inflammation

Indications

Symptoms associated with intestinal flora imbalance such as:

Diarrhoea, constipation, bloating and flatulence

Colonic mucosal inflammation.

Irritable Bowel Syndrome

Inflammatory Bowel Disease

Acute diarrhoea

Antibiotic-induced diarrhea

Traveller's diarrhea

Suggested Use:

1 Scoop daily – dissolved in water or juice or can be added to food.

Caution:

None noted.

Warning:

Probiotics are contraindicated in those hypersensitive to any component of a probiotic-containing product.

ProB) Plus 1

This unique probiotic blend contains 20 billion shelf-stable probiotic bacteria, with Millet sprout powder and Astragalus Polysaccharide.

Astragalus Polysaccharide promotes probiotic growth and modulates the immune system providing an effective prebiotic effect.

Research

Astragalus polysaccharide reduces the severity of acute pancreatitis under a high-fat diet through enriching L. reuteri and propionate.

PMID: 39837455

Acute pancreatitis (AP) is a severe digestive disorder, worsened by a high-fat diet (HFD) through inflammation and gut microbiota disruption. Astragalus polysaccharides (APS), known for their anti-inflammatory properties, may alleviate HFD-induced exacerbation of AP by modulating gut microbiota. This study investigates the effect of APS on AP severity under a HFD (HAP). Results show that HFD significantly worsens AP, with elevated serum enzymes, pro-inflammatory cytokines, and pancreatic damage. Single-cell RNA sequencing revealed increased ICAM1+ neutrophils and activation of the NF-κB/necroptosis pathway in HAP mice. Treatment with APS reduced neutrophil infiltration, downregulated NF-κB, and suppressed necroptosis. APS also restored gut microbiota balance, boosting Lactobacillus reuteri (L. reuteri) and propionate (PA) levels. Interventions with L. reuteri or PA reduced HAP severity, with combined treatment showing synergistic effects. These findings suggest that the protective effect of APS is mediated by microbiota-dependent mechanisms, highlighting the gut-pancreas axis as a potential therapeutic target for AP.

Research

Identification of the key physiological characteristics of Lactobacillus plantarum strains for ulcerative colitis alleviation.

DSS Resulted in the substantial expression of pro-inflammatory cytokines in colon tissue. However, this expression was reduced after the ingestion of L. plantarum strains.

L. plantarum CCFM8610 had the strongest inhibiting effect on the expression of pro-inflammatory cytokines. This strain significantly inhibited the expression of IL-1β, IL-6, IL-17F, and TNF-α and restored MPO to the level of the control group.

Next, the effect of L. plantarum N13 was also prominent. This strain inhibited all of the pro-inflammatory cytokines. However, except for IFN-γ (Fig.6E), the inhibitory effects were weaker than those of L. plantarum CCFM8610. L. plantarum CCFM382 did not show any significant inhibiting effects.